Sernova Corp (DE:PSH0)
XETRA:PSH0
PSH0 Stock Chart & Stats
€0.11
--
Market closed
€0.11
--
Day’s Range― - ―
52-Week Range€0.06 - €0.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.46K
Market Cap
€34.44M
Enterprise Value€72.61M
Total Cash (Recent Filing)€576.22K
Total Debt (Recent Filing)€17.55M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Jun 12, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding347,726,350
10 Day Avg. Volume5,531
30 Day Avg. Volume4,462
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€187.25K
Bulls Say, Bears Say
Bulls Say
Proprietary Implantable PlatformSernova’s Cell Pouch System is a platform technology targeting durable cell replacement for chronic disease (notably diabetes). As a platform, successful clinical validation could create a sustainable competitive moat and multiple upstream partnership or licensing paths beyond a single product.
Moderation In Cash BurnTrailing improvement in operating cash outflow reflects better cash discipline or milestone timing and extends the company’s funding runway. A sustained moderation reduces short-term financing pressure and supports continued clinical development without immediate dilutive financing.
Smaller Net Losses TrendProgress toward smaller net losses indicates the company is managing expenses or realizing operating efficiencies. For a pre-revenue biotech, a consistent reduction in losses improves financial stability and increases the odds of reaching key clinical inflection points before requiring major new capital.
Bears Say
Pre-revenue Business ModelSernova remains pre-revenue with no commercial product sales, meaning its long-term viability depends on successful clinical outcomes and external financing. Without recurring revenues, the company faces ongoing dilution risk and limited internal cash generation to fund development.
Elevated Balance-sheet RiskDeeply negative equity and a marked increase in debt signal constrained financial flexibility and a higher probability of needing additional capital. This structural balance-sheet weakness raises refinancing, covenant, or dilution risks that could impede long-term program execution.
Negative Cash GenerationPersistent negative operating and free cash flow underscore ongoing cash burn typical of development-stage biotech. With TTM FCF growth still negative, the company remains dependent on external funding, which can delay programs or force unfavorable financing terms and strategic compromises.
Sernova News
PSH0 FAQ
What was Sernova Corp’s price range in the past 12 months?
Sernova Corp lowest stock price was €0.06 and its highest was €0.20 in the past 12 months.
What is Sernova Corp’s market cap?
Sernova Corp’s market cap is €34.44M.
When is Sernova Corp’s upcoming earnings report date?
Sernova Corp’s upcoming earnings report date is Jun 12, 2026 which is in 64 days.
How were Sernova Corp’s earnings last quarter?
Sernova Corp released its earnings results on Mar 13, 2026. The company reported -€0.006 earnings per share for the quarter, the consensus estimate of -€0.006 by €0.
Is Sernova Corp overvalued?
According to Wall Street analysts Sernova Corp’s price is currently Overvalued.
Does Sernova Corp pay dividends?
Sernova Corp does not currently pay dividends.
What is Sernova Corp’s EPS estimate?
Sernova Corp’s EPS estimate is >-0.01.
How many shares outstanding does Sernova Corp have?
Sernova Corp has 347,726,350 shares outstanding.
What happened to Sernova Corp’s price movement after its last earnings report?
Sernova Corp reported an EPS of -€0.006 in its last earnings report, expectations of -€0.006. Following the earnings report the stock price went down -9.244%.
Which hedge fund is a major shareholder of Sernova Corp?
Currently, no hedge funds are holding shares in DE:PSH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sernova Corp
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
Technical Analysis
Covalon Technologies
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―
Defence Therapeutics
―